Broad-spectrum co-administered gastrointestinal substances

Broad-spectrum co-administered gastrointestinal substances is not a single molecular target but a clinical and regulatory classification for a diverse group of agents that modify the gastrointestinal environment. This category includes acid-reducing agents like proton pump inhibitors and antacids, as well as adsorbents and chelators that are frequently taken concomitantly with other therapeutic drugs (FDA, 2023). These substances are significant in pharmacology because they can drastically alter the absorption and bioavailability of 'victim' drugs, potentially leading to clinical treatment failure or adverse effects (Clinical Pharmacology & Therapeutics, 2019). In drug development, these substances are studied to identify potential pH-dependent drug-drug interactions (DDIs) or physical interactions that occur within the gut lumen. For example, increasing gastric pH can decrease the dissolution of poorly soluble basic drugs, while metal ions in antacids can chelate with antibiotics like tetracyclines or fluoroquinolones, preventing their systemic absorption (PubMed, 2021). Biotech analysts monitor these interactions to ensure proper dosing instructions and to mitigate risks during clinical trials where patients may be using over-the-counter GI medications.

Other names

Concomitant gastrointestinal medicationsGastric pH-altering agentsGI-modifying substancesAcid-reducing agents (ARAs)Gastrointestinal interacting substances

These substances interfere with the pharmacokinetics of co-administered drugs by altering the gastrointestinal environment. Mechanisms include increasing gastric pH, which affects the solubility of weakly basic or acidic drugs; physical adsorption of drug molecules to the substance surface; or chemical chelation with multivalent cations (e.g., Ca2+, Mg2+, Al3+), forming non-absorbable complexes (FDA Guidance, 2023; StatPearls, 2023).